IYT 0.71IHF 0PTF -4.96STN.TO 2.39BIP.UN.TO 0.78NFLX 4.24RKLB 5.11ASTS 6.5
Moderna (MRNA)

NASDAQ:MRNA

Moderna (MRNA)

67.53
+7.78 (13.02%)
as of Jun 26, 2026, 2:44:55 pm Market Open.
142 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 26, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Moderna (MRNA-Q) has shown significant recovery and momentum in recent months, with a notable 72% increase in Q1 and a nearly 50% rise in January, making it one of the best performers on the S&P. The company has addressed some legal challenges that were previously weighing on its stock and gained FDA approval for its new flu vaccine. Despite potential concerns about the vaccine industry's future, Moderna is optimistic about returning to revenue growth by 2026 and has aspirations in the personalized cancer vaccine space. However, experts caution that the biotech market can be highly volatile and uncertain, and there are questions about Moderna's ability to leverage its technology in adjacent markets. The overall sentiment is mixed, reflecting excitement for future growth against the backdrop of inherent industry risks.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Fair Value
review icon
Similar
Pfizer, PFE
BUY

Moderna(MRNA)

Oct 22, 2021
It's down 5% today, but he has conviction for it. Less than 10x earnings this year and next, and boasts one of the best drug pipelines in the industry.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
$321.44

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Moderna(MRNA)

Oct 07, 2021
(A Top Pick Apr 07/21, Up 125%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with MNRA has triggered its stop at $300. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment return of 78%.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$315.74

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
SELL

Moderna(MRNA)

Oct 04, 2021
He owned it and sold it way too early. All the good news is in this stock for the next two years. It was well ahead of the fundamentals. Watch for another opportunity with them. It's fully valued right now.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$325.82

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

Sep 24, 2021

It had a huge run. When the pandemic ends, the prices on their shots will leap from $25 to $150-200 which is normal for booster shots. Think of the profitability and their pipeline of 34 drugs.

Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital PartnersUnlock Rating
$454.60

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Moderna(MRNA)

Sep 17, 2021
In the news for their vaccine. It's pretty much all their business right now. Total revenue was $60M, but their market cap is $170B. The question is, are their legs with the vaccine franchise. They have lots of drugs in their pipeline, but there is a lot of risk.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$424.16

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Moderna(MRNA)

Aug 05, 2021
(A Top Pick Apr 08/21, Up 213.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA is progressing well. We recommend trailing up the stop (from $175) to $300. Along with the previous recommendation to cover half the position, this would all but guarantee a net investment return of 78% if triggered.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$419.00

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

Jul 21, 2021
Their targeted cancer vaccines will dwarf their revenues from even Covid. These are really smart guys and they're making tons of money.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$321.11

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Moderna(MRNA)

Jun 29, 2021
(A Top Pick Apr 08/21, Up 76.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRN is progressing well. We now recommend trailing up the stop (from $134) to $175. If triggered, this would all but guarantee a net investment return of 31%, when considering our previous recommendation to cover 50% of the holding.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$235.55

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

Jun 07, 2021

He prefers it to Novavax, despite Novavax's good run today, because Moderna can do a lot more with its formulation.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$221.26

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

May 07, 2021

Novavax Novavax is not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$163.14

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Moderna(MRNA)

Apr 27, 2021
(A Top Pick Apr 08/21, Up 31.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has achieved our $175 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop to $134, just above the original recommended entry level. This would all but guarantee a minimum investment return exceeding 15%.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$183.35

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Moderna(MRNA)

Apr 08, 2021
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$133.29

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

Mar 15, 2021
A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$143.65

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Moderna(MRNA)

Jan 18, 2021
The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$129.65

Stock price when the opinion was issued

$66.29

As of Jun 26, 2026. Market Open.

Pharma & Healthcare
Showing 46 to 60 of 64 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MNS.TO 0.66$46.05
MPWR -109.56$1328.74
MSFT 15.79$368.62
DAL 0.585$92.695
OTEX.TO 0.73$31.1

Today's Top Picks

IYT 0.71$87.35
IHF 0$54.45
PTF -4.96$127.28
STN.TO 2.39$98.71
BIP.UN.T… 0.78$52.4

Popular Articles

Latest Sell Signals

NVO 0.57$48.21
TRP.TO -0.34$99.26
RY.TO -0.95$288.17
TD.TO -0.54$170.36
ATD.TO -0.43$93.14

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video